Cluster Of Differentiation 3 (CD3) Antibody Global Market Report 2025
상품코드:1889339
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
CD3 항체 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 17억 5,000만 달러로 평가되었고, 2025년에는 19억 9,000만 달러에 달할 것으로 추정되며, CAGR 13.8%로 성장이 예상되고 있습니다. 지난 수년간의 성장은 혈액암의 발생률 상승, 종양 전문의에 의한 면역요법 도입 확대, 종양학 임상시험에 대한 투자 증가, 생물학적 암 치료에 대한 병원 지출 급증, 헬스케어 적용 범위 확대 및 암 치료비 상환 프로그램 확충, 환자에서의 면역 기반 암 치료에 대한 인식 향상에 기인한 것으로 보입니다.
CD3 항체 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 33억 달러에 달할 것으로 예측되며, CAGR 13.5%로 성장할 전망입니다. 예측 기간에 있어서의 성장 요인으로서는 면역 표적 요법으로 치료 가능한 고형 종양의 유병률 상승, 정밀하고 개별화된 종양 치료에 대한 수요 증가, 암 연구 개발에 대한 정부 자금 확대, 세계의 암 진단 스크리닝 프로그램 확충, 신흥국에서의 표적 생물학적 제제 사용 증가 등을 들 수 있습니다. 예측 기간 주요 동향으로는 이중 특이성 항체 공학에 있어서 기술적 진보, 독성 저감을 위한 항체 인간화 기술의 진전, 강력한 면역 활성화를 실현하는 모듈러 항체 설계의 혁신, 특이성 향상을 위한 종양 표적화 플랫폼의 개발, 고수량 및 고안정성을 실현하는 항체 제조 기술의 혁신 등을 들 수 있습니다.
암 이환율의 상승은 향후 CD3 항체 시장의 성장을 가속할 것으로 예측됩니다. 암 이환율이란 특정 시점에서 새롭게 진단된 분과 과거에 진단된 분을 아우르는 암 경력이 있는 생존자의 총수를 말합니다. 부적절한 식생활, 흡연, 음주, 환경오염물질에 대한 노출 등 생활 습관과 관련된 위험에 의해 다양한 암을 발병할 위험성이 높아지고 있기 때문에 암 이환율은 증가하는 경향이 있습니다. CD3 항체는 T세포를 활성화하고 악성 세포를 표적으로 하도록 유도함으로써 암 치료를 지원합니다. 면역 반응의 효율을 높이기 위해 혈액 종양 및 고형 종양의 치료에 효과적입니다. 이 표적 치료는 치료의 정확성 및 환자의 예후를 향상시킵니다. 예를 들어, 호주 정부 기관인 Cancer Australia의 보고에 의하면, 2025년 2월 시점에서 2024년의 신규 췌장암 환자수는 4641명(남성 2414명, 여성 2227명)이었습니다. 이처럼 암의 유병률 상승이 CD3 항체 시장의 성장을 견인하고 있습니다.
CD3 항체 시장에서 사업을 전개하는 주요 기업은 치료 효과의 향상, 암세포에 대한 표적성 강화, 다제 내성 환자의 재발 억제를 목적으로 한, 이중 특이성 항체 등 선진적 치료법의 개발에 주력하고 있습니다. 이중 특이성 항체란 2가지 다른 항원에 동시에 결합하도록 설계된 선진적 생물학적 요법으로, 환자 자신의 면역세포를 재유도하여 암세포를 공격 및 제거하는 기능이 있습니다. 예를 들어, 2023년 8월에는 미국에 본사를 둔 제약회사 존슨 엔드 존슨사가 재발성 또는 난치성 다발성 골수종 환자용으로 설계된 이중특이성 T세포 참여 항체 요법 '탈베이(탈케타마브 TGVS)'에 대해 미국 식품의약국(FDA)의 승인을 취득 본 요법은 T 세포 상의 CD3 및 골수종 세포 상의 G 단백질 공액 수용체 클래스 C 그룹 5 멤버 D(GPRC5D)에 결합하고, T 세포의 정밀한 유도나 개별화 키메라 항원 수용체 T 세포(CAR-T 세포)의 제조를 필요로 하지 않는 즉용성의 이점을 갖추고 있습니다. 이로 인해 다제 내성 환자에서 치료 접근성, 면역 매개 종양 살상 효과, 치료 성과 향상이 기대됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 CD3 항체 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 CD3 항체 시장 : 성장률 분석
세계의 CD3 항체 시장 실적 : 규모 및 성장(2019-2024년)
세계의 CD3 항체 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 CD3 항체 시장 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 CD3 항체 시장 : 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일클론 항체
이중특이적 항체
항체 약물 복합체
단편 결정화(Fc) 엔지니어링 제품
기타 제품 유형
세계의 CD3 항체 시장 : 분자량별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
저분자량
중분자량
고분자량
세계의 CD3 항체 시장 : 제제 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
수성 제제
비수계 제제
세계의 CD3 항체 시장 : 치료 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
암 면역요법
자가면역 질환
이식거절 반응
감염증
기타 용도
세계의 CD3 항체 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
연구기관
제약기업
수탁연구기관
기타 최종 사용자
세계의 CD3 항체 시장 : 단일클론항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
인간화 단일클론 항체
완전 인간 단일클론 항체
키메라 단일클론 항체
마우스 단일클론 항체
재조합 단일클론 항체
세계의 CD3 항체 시장 : 이중특이성 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
T세포 인게이지형 이특이성 항체
이중 면역 체크포인트 이중특이성 항체
사이토카인 조절형 이중특이성 항체
종양 관련 항원을 표적으로 하는 이중특이성 항체
세계의 CD3 항체 시장 : 항체 약물 복합체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
페이로드 강화형 컨쥬게이트
링커 최적화 컨쥬게이트
종양 표적화 컨쥬게이트
면역자극성 컨쥬게이트
세계의 CD3 항체 시장 : 단편 결정화 가능(Fc) 엔지니어링 제품 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단편 결정화 가능(Fc) 당쇄 개변 항체
단편 결정화가능(Fc) 변이체 항체
단편 결정화 가능(Fc) 융합 치료용 단백질
반감기 연장형 Fc 결정화 가능 단편 제품
세계의 CD3 항체 시장 : 기타 제품 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일 도메인 항체
폴리클로날 항체
수용체 융합 단백질
설계 면역 활성화 인자
제7장 지역별 및 국가별 분석
세계의 CD3 항체 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 CD3 항체 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
CD3 항체 시장 : 경쟁 구도
CD3 항체 시장 : 기업 프로파일
Johnson and Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Incorporated : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bristol-Myers Squibb Company
Thermo Fisher Scientific Incorporated
Eli Lilly and Company
Amgen Inc.
Gilead Sciences Inc.
Merck KGaA
Bio-Rad Laboratories Incorporated
Miltenyi Biotec BV and Co KG
Harbour BioMed Holding Limited
Zymeworks Inc.
Adimab LLC
GeneTex Incorporated
Santa Cruz Biotechnology Incorporated
FabGennix Incorporated
EXBIO Praha spol sro
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
CD3 항체 시장(2029년) : 새로운 기회를 제공하는 국가
CD3 항체 시장(2029년) : 새로운 기회를 제공하는 부문
CD3 항체 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Cluster of differentiation 3 (CD3) antibody is a monoclonal antibody that targets the CD3 complex located on the surface of T lymphocytes. It is mainly used to influence T cell activity, making it important in immunotherapy and research applications. It assists in T cell activation, depletion, or redirection, depending on therapeutic purpose.
The main product types of cluster of differentiation 3 (CD3) antibody are monoclonal antibodies, bispecific antibodies, antibody drug conjugates, fragment crystallizable engineering products, and others. Monoclonal antibodies are laboratory produced molecules designed to identify and bind to a single specific antigen, supporting targeted diagnosis or treatment. The different molecular weights involved are low molecular weight, medium molecular weight, and high molecular weight, while the formulation types include aqueous formulations and non aqueous formulations. It is applied in cancer immunotherapy, autoimmune diseases, transplant rejection, infectious diseases, and others, and serves end users such as hospitals, research institutes, pharmaceutical companies, contract research organizations, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The cluster of differentiation 3 (CD3) antibody market research report is one of a series of new reports from The Business Research Company that provides cluster of differentiation 3 (CD3) antibody market statistics, including the cluster of differentiation 3 (CD3) antibody industry global market size, regional shares, competitors with the cluster of differentiation 3 (CD3) antibody market share, detailed cluster of differentiation 3 (CD3) antibody market segments, market trends, and opportunities, and any further data you may need to thrive in the cluster of differentiation 3 (CD3) antibody industry. This cluster of differentiation 3 (CD3) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cluster of differentiation 3 (CD3) antibody market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.99 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to rising incidence of hematological cancers, increasing adoption of immunotherapy by oncologists, growing investment in oncology clinical trials, surge in hospital spending on biologic cancer treatments, expansion of healthcare coverage and cancer reimbursement programs, and rising awareness of immune based cancer care among patients.
The cluster of differentiation 3 (CD3) antibody market size is expected to see rapid growth in the next few years. It will grow to $3.30 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to rising prevalence of solid tumors treatable with immune targeted therapies, increasing demand for precision and personalized oncology treatments, growing government funding for cancer research and drug development, expansion of cancer diagnostic screening programs worldwide, and rising use of targeted biologics in emerging economies. Major trends in the forecast period include technological advancements in bispecific antibody engineering, progress in antibody humanization for reduced toxicity, innovations in modular antibody design for stronger immune activation, developments in tumor targeting platforms for enhanced specificity, and innovations in antibody manufacturing for higher yield and stability.
The rising prevalence of cancer is expected to propel the growth of the cluster of differentiation 3 CD3 antibody market going forward. Prevalence of cancer refers to the total number of people, both newly diagnosed and previously diagnosed, who are alive with a history of cancer at a specific point in time. The prevalence of cancer is increasing due to lifestyle related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. Cluster of differentiation 3 CD3 antibodies aid in cancer treatment by activating and redirecting T cells to target malignant cells. They enhance immune response efficiency, making them effective in treating hematologic and solid tumors. This targeted approach improves therapeutic precision and patient outcomes. For instance, in February 2025, according to Cancer Australia, an Australia based government agency, there were 4641 new pancreatic cancer cases in 2024, with 2414 in males and 2227 in females. Therefore, the rising prevalence of cancer is driving the growth of the cluster of differentiation 3 CD3 antibody market.
Major companies operating in the cluster of differentiation 3 CD3 antibody market are focusing on developing advanced treatments such as bispecific antibodies to boost treatment efficacy, enhance targeting of cancer cells, and reduce relapse in heavily pretreated patients. Bispecific antibodies refer to advanced biologic therapies engineered to bind simultaneously to two different antigens, redirecting the patient's own immune cells to attack and eliminate cancer cells. For instance, in August 2023, Johnson and Johnson, a US based pharmaceutical company, received US Food and Drug Administration approval for Talvey talquetamab tgvs, a bispecific T cell engaging antibody therapy designed for patients with relapsed or refractory multiple myeloma. The therapy binds CD3 on T cells and G protein coupled receptor class C group 5 member D GPRC5D on myeloma cells, featuring capabilities such as precise T cell redirection and off the shelf use without the need for individualized chimeric antigen receptor T cell CAR T cell manufacturing. It improves treatment accessibility, immune mediated tumor killing, and therapeutic outcomes in heavily pretreated patients.
In December 2023, Danaher Corporation, a US based biotechnology company, acquired Abcam plc for five point seven billion dollars. With this acquisition, Danaher aims to strengthen its position in the life sciences and proteomics market, expanding its portfolio of research reagents, antibodies, and related solutions for drug discovery and diagnostics. Abcam plc is a UK based life sciences company offering CD3 antibodies for immunology and cancer research.
Major companies operating in the cluster of differentiation 3 (cd3) antibody market are Johnson and Johnson, Roche Holding AG, Pfizer Incorporated, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Incorporated, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Merck KGaA, Bio-Rad Laboratories Incorporated, Miltenyi Biotec B V and Co KG, Harbour BioMed Holding Limited, Zymeworks Inc., Adimab LLC, GeneTex Incorporated, Santa Cruz Biotechnology Incorporated, FabGennix Incorporated, EXBIO Praha spol s r o
North America was the largest region in the cluster of differentiation 3 (CD3) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cluster of differentiation 3 (CD3) antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cluster of differentiation 3 (CD3) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cluster of differentiation 3 (CD3) antibody market consists of sales of CD3 detection kits, flow cytometry reagents, fluorescent-labeled CD3 antibodies, immunohistochemistry reagents, western blot reagents, and CD3 diagnostic test kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cluster Of Differentiation 3 (CD3) Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cluster of differentiation 3 (cd3) antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cluster of differentiation 3 (cd3) antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cluster of differentiation 3 (cd3) antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Monoclonal Antibodies; Bispecific Antibodies; Antibody-Drug Conjugates; Fragment Crystallizable (Fc) Engineering Products; Other Product Types
2) By Molecular Weight: Low Molecular Weight; Medium Molecular Weight; High Molecular Weight
3) By Formulation Type: Aqueous Formulations; Non-Aqueous Formulations
4) By Therapeutic Application: Cancer Immunotherapy; Autoimmune Diseases; Transplant Rejection; Infectious Diseases; Other Applications
5) By End User: Hospitals; Research Institutes; Pharmaceutical Companies; Contract Research Organizations; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies; Recombinant Monoclonal Antibodies
3) By Antibody Drug Conjugates: Payload Enhanced Conjugates; Linker Optimized Conjugates; Tumor Targeted Conjugates; Immune Stimulating Conjugates
4) By Fragment Crystallizable (Fc) Engineering Products: Fragment Crystallizable (Fc) Glycoengineered Antibodies; Fragment Crystallizable (Fc) Mutant Antibodies; Fragment Crystallizable (Fc) Fused Therapeutic Proteins; Extended Half Life Fragment Crystallizable (Fc) Products
5) By Other Product Types: Single Domain Antibodies; Polyclonal Antibodies; Receptor Fusion Proteins; Engineered Immune Activators
Companies Mentioned: Johnson and Johnson; Roche Holding AG; Pfizer Incorporated; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Incorporated; Eli Lilly and Company; Amgen Inc.; Gilead Sciences Inc.; Merck KGaA; Bio-Rad Laboratories Incorporated; Miltenyi Biotec B V and Co KG; Harbour BioMed Holding Limited; Zymeworks Inc.; Adimab LLC; GeneTex Incorporated; Santa Cruz Biotechnology Incorporated; FabGennix Incorporated; EXBIO Praha spol s r o
Countries:
Table of Contents
1. Executive Summary
2. Cluster Of Differentiation 3 (CD3) Antibody Market Characteristics
3. Cluster Of Differentiation 3 (CD3) Antibody Market Trends And Strategies
4. Cluster Of Differentiation 3 (CD3) Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Cluster Of Differentiation 3 (CD3) Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Cluster Of Differentiation 3 (CD3) Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cluster Of Differentiation 3 (CD3) Antibody Market Growth Rate Analysis
5.4. Global Cluster Of Differentiation 3 (CD3) Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cluster Of Differentiation 3 (CD3) Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cluster Of Differentiation 3 (CD3) Antibody Total Addressable Market (TAM)
6. Cluster Of Differentiation 3 (CD3) Antibody Market Segmentation
6.1. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Bispecific Antibodies
Antibody-Drug Conjugates
Fragment Crystallizable (Fc) Engineering Products
Other Product Types
6.2. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low Molecular Weight
Medium Molecular Weight
High Molecular Weight
6.3. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aqueous Formulations
Non-Aqueous Formulations
6.4. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Immunotherapy
Autoimmune Diseases
Transplant Rejection
Infectious Diseases
Other Applications
6.5. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
Pharmaceutical Companies
Contract Research Organizations
Other End-Users
6.6. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Humanized Monoclonal Antibodies
Fully Human Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Murine Monoclonal Antibodies
Recombinant Monoclonal Antibodies
6.7. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.8. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Payload Enhanced Conjugates
Linker Optimized Conjugates
Tumor Targeted Conjugates
Immune Stimulating Conjugates
6.9. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Sub-Segmentation Of Fragment Crystallizable (Fc) Engineering Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fragment Crystallizable (Fc) Glycoengineered Antibodies
Fragment Crystallizable (Fc) Mutant Antibodies
Fragment Crystallizable (Fc) Fused Therapeutic Proteins
Extended Half Life Fragment Crystallizable (Fc) Products
6.10. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single Domain Antibodies
Polyclonal Antibodies
Receptor Fusion Proteins
Engineered Immune Activators
7. Cluster Of Differentiation 3 (CD3) Antibody Market Regional And Country Analysis
7.1. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cluster Of Differentiation 3 (CD3) Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Cluster Of Differentiation 3 (CD3) Antibody Market
8.1. Asia-Pacific Cluster Of Differentiation 3 (CD3) Antibody Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Cluster Of Differentiation 3 (CD3) Antibody Market
9.1. China Cluster Of Differentiation 3 (CD3) Antibody Market Overview
9.2. China Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Cluster Of Differentiation 3 (CD3) Antibody Market
10.1. India Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Cluster Of Differentiation 3 (CD3) Antibody Market
11.1. Japan Cluster Of Differentiation 3 (CD3) Antibody Market Overview
11.2. Japan Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Cluster Of Differentiation 3 (CD3) Antibody Market
12.1. Australia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Cluster Of Differentiation 3 (CD3) Antibody Market
13.1. Indonesia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Cluster Of Differentiation 3 (CD3) Antibody Market
14.1. South Korea Cluster Of Differentiation 3 (CD3) Antibody Market Overview
14.2. South Korea Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Cluster Of Differentiation 3 (CD3) Antibody Market
15.1. Western Europe Cluster Of Differentiation 3 (CD3) Antibody Market Overview
15.2. Western Europe Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Cluster Of Differentiation 3 (CD3) Antibody Market
16.1. UK Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Cluster Of Differentiation 3 (CD3) Antibody Market
17.1. Germany Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Cluster Of Differentiation 3 (CD3) Antibody Market
18.1. France Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Cluster Of Differentiation 3 (CD3) Antibody Market
19.1. Italy Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Cluster Of Differentiation 3 (CD3) Antibody Market
20.1. Spain Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Cluster Of Differentiation 3 (CD3) Antibody Market
21.1. Eastern Europe Cluster Of Differentiation 3 (CD3) Antibody Market Overview
21.2. Eastern Europe Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Cluster Of Differentiation 3 (CD3) Antibody Market
22.1. Russia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Cluster Of Differentiation 3 (CD3) Antibody Market
23.1. North America Cluster Of Differentiation 3 (CD3) Antibody Market Overview
23.2. North America Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Cluster Of Differentiation 3 (CD3) Antibody Market
24.1. USA Cluster Of Differentiation 3 (CD3) Antibody Market Overview
24.2. USA Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Cluster Of Differentiation 3 (CD3) Antibody Market
25.1. Canada Cluster Of Differentiation 3 (CD3) Antibody Market Overview
25.2. Canada Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Cluster Of Differentiation 3 (CD3) Antibody Market
26.1. South America Cluster Of Differentiation 3 (CD3) Antibody Market Overview
26.2. South America Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Cluster Of Differentiation 3 (CD3) Antibody Market
27.1. Brazil Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Cluster Of Differentiation 3 (CD3) Antibody Market
28.1. Middle East Cluster Of Differentiation 3 (CD3) Antibody Market Overview
28.2. Middle East Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Cluster Of Differentiation 3 (CD3) Antibody Market
29.1. Africa Cluster Of Differentiation 3 (CD3) Antibody Market Overview
29.2. Africa Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Molecular Weight, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cluster Of Differentiation 3 (CD3) Antibody Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Cluster Of Differentiation 3 (CD3) Antibody Market Competitive Landscape And Company Profiles
30.1. Cluster Of Differentiation 3 (CD3) Antibody Market Competitive Landscape
30.2. Cluster Of Differentiation 3 (CD3) Antibody Market Company Profiles
30.2.1. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Pfizer Incorporated Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Cluster Of Differentiation 3 (CD3) Antibody Market Other Major And Innovative Companies
31.1. Bristol-Myers Squibb Company
31.2. Thermo Fisher Scientific Incorporated
31.3. Eli Lilly and Company
31.4. Amgen Inc.
31.5. Gilead Sciences Inc.
31.6. Merck KGaA
31.7. Bio-Rad Laboratories Incorporated
31.8. Miltenyi Biotec B V and Co KG
31.9. Harbour BioMed Holding Limited
31.10. Zymeworks Inc.
31.11. Adimab LLC
31.12. GeneTex Incorporated
31.13. Santa Cruz Biotechnology Incorporated
31.14. FabGennix Incorporated
31.15. EXBIO Praha spol s r o
32. Global Cluster Of Differentiation 3 (CD3) Antibody Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Cluster Of Differentiation 3 (CD3) Antibody Market
34. Recent Developments In The Cluster Of Differentiation 3 (CD3) Antibody Market
35. Cluster Of Differentiation 3 (CD3) Antibody Market High Potential Countries, Segments and Strategies
35.1 Cluster Of Differentiation 3 (CD3) Antibody Market In 2029 - Countries Offering Most New Opportunities
35.2 Cluster Of Differentiation 3 (CD3) Antibody Market In 2029 - Segments Offering Most New Opportunities
35.3 Cluster Of Differentiation 3 (CD3) Antibody Market In 2029 - Growth Strategies
